3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
9
Nivolumab
4
Magnetic Resonance Spectroscopy
3
spartalizumab
2
Ipilimumab
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Drug Therapy
2
Cisplatin
2
zenocutuzumab
1
venetoclax
1
ulixertinib
1
trametinib
1
tislelizumab
1
seribantumab
1
rovalpituzumab tesirine
1
pazopanib
1
neratinib
1
margetuximab
1
lenvatinib
1
entrectinib
1
durvalumab
1
cobimetinib
1
cemiplimab
1
budigalimab
1
bemarituzumab
1
atezolizumab
1
alectinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
bemarituzumab
×
Head & Neck
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled